ImmunoGen Announces Promising Final Survival and Efficacy Data from SORAYA Trial at SGO Annual Meeting

ImmunoGen, Inc. (Nasdaq: IMGN) is proud to present final overall survival data and an evaluation of sequence of therapy in the pivotal SORAYA trial of mirvetuximab soravtansine in patients with folate receptor alpha-high platinum-resistant ovarian cancer who had been previously treated with bevacizumab.

This exciting presentation will take place in a plenary session at the 2023 Society of Gynecologic Oncology (SGO) Annual Meeting in Tampa, Florida, on Saturday, March 25. These groundbreaking findings will provide new insight into the treatment of this form of ovarian cancer.


ImmunoGen is revolutionizing cancer treatment with next-generation antibody-drug conjugates (ADCs). We are determined to disrupt the progression of cancer and give patients more good days with our targeted therapies, which are designed to provide greater anti-tumor activity and more favorable tolerability profiles. This is our commitment to TARGET A BETTER NOW™.

Leave a Comment